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ABSTRACT
Abnormal expression of the chemokine receptor CXCR4 plays an essential role in 
tumor cell dissemination and disease progression. However, the significance of CXCR4 
overexpression in de novo diffuse large B cell lymphoma (DLBCL) is unknown. In 743 
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INTRODUCTION
CXCR4 (CD184) is a chemokine receptor specific 
for CXCL12. The CXCL12/CXCR4 axis is critical 
to the retention of B-cell precursors in bone marrow 
(BM), homing of B lymphocytes to lymph nodes, and 
infiltration of T-cells and other immune cells expressing 
CXCR4 [1]. Signaling molecules, physiological stimuli, 
and co-translational modifications control the expression, 
oligomerization, internalization, and degradation of 
CXCR4. CD63, interleukin 21, hypoxia-inducible factor 
1 alpha, nuclear factor-kappa B (NF-κB), CREB3, PAX3-
FKHR, Wnt, Notch, and PI3K/Akt pathways positively 
regulate CXCR4 levels. In contrast, p53 [2], tumor 
necrosis factor-alpha (TNF-α), interferon-gamma, and 
ubiquitination modification negatively regulate CXCR4 
levels [3-6]. Activated CXCL12/CXCR4 in turn activates 
signaling cascades such as PI3K/Akt, mitogen-activated 
protein kinase (MAPK), integrin, tyrosine kinases, and 
G-proteins [3,4].
Abnormal CXCR4 surface expression in solid 
tumors, has been shown to be responsible for their 
metastasis to particular organs with high CXCL12 
levels (e.g., lymph nodes, bones, and BM) [3,7,8], and 
have prognostic significance for disease progression in 
breast, colorectal, and renal cancers, and hepatocellular 
carcinoma [3,9,10]. In leukemia, CXCR4 expression 
conferred leukemic blasts with a higher capacity to seed 
into BM niches, thereby protecting leukemic cells from 
chemotherapy-induced apoptosis, and was correlated 
with shorter disease-free survival [3,11-15]. Conversely, 
neutralizing the interactions of CXCL12/CXCR4 
disrupted metastasis, induced apoptosis, and increased 
chemosensitivity in solid cancers and leukemia [7,16-18]. 
Diffuse large B cell lymphoma (DLBCL) is the most 
common type of non-Hodgkin lymphoma among adults. 
DLBCL typically presents as a nodal or extranodal mass 
with rapid tumor growth. Extranodal DLBCL (primary 
sites are outside the lymphatic system) accounts for 30-
40% of DLBCL. Approximately 70% of DLBCLs have at 
least one and 30% have multiple extranodal involvements 
[19,20]. With the standard immunochemotherapy regimen 
consisting of rituximab, cyclophosphamide, doxorubicin, 
vincristine, and prednisone (R-CHOP), approximately 
one-third of DLBCL patients develop relapsed/refractory 
disease [21]. Gene expression profiling (GEP) divides 
DLBCL into two main subtypes according to cell-of-
origin gene signatures: germinal center B-cell-like (GCB), 
arising from the germinal center (GC) compartment, 
and activated B-cell-like (ABC), arising from post-GC 
plasmablastic cells [22]. During the development of 
mature B-cells, CXCR4 is expressed at higher levels in 
centroblasts localized in the CXCL12-rich dark zone 
than in centrocytes in the light zone of the GC. CXCR4 
is also upregulated during plasma cell differentiation and 
expressed in memory B-cells [23-27].
The prognostic significance of CXCR4 expression in 
lymphoma, which has different CXCL12 gradients at the 
primary sites compared to other types of cancers [28], has 
not been well studied. Moreover, it is unknown whether 
the use of a CXCL12/CXCR4 antagonist in nodal DLBCL 
will result in lymphoma cell mobilization and increased 
spreading [8,29-32]. Very recently, CXCR4 expression was 
correlated to disease progression in 12 cases of primary 
testicular DLBCL [33] and poor survival of 94 DLBCL 
cases [34]. In 20 patients with non-Hodgkin lymphomas, 
a significant decrease in CXCR4 mRNA expression in the 
BM after treatment correlated with a significantly lower 
risk of death [35]. In this study, we assessed the surface 
expression of CXCR4 using immunohistochemistry (IHC) 
in 743 patients with de novo DLBCL, compared the gene 
expression profiles and protein expression of biomarkers 
between CXCR4+ and CXCR4– DLBCLs, and evaluated 
the prognostic value of CXCR4 expression. We also tested 
the effect of the high-affinity CXCL12/CXCR4 inhibitor 
BTK140 (4F-benzoyl-TN14003) on DLBCL cells in 
vitro, which not only inhibits CXCL12/CXCR4 mediated 
adhesion and migration [36], overcomes stromal cells-
patients with de novo diffuse large B cell lymphoma (DLBCL) who received standard 
Rituximab-CHOP immunochemotherapy, we assessed the expression of CXCR4 and 
dissected its prognostic significance in various DLBCL subsets. Our results showed that 
CXCR4+ patients was associated with male, bulky tumor, high Ki-67 index, activated 
B-cell-like (ABC) subtype, and Myc, Bcl-2 or p53 overexpression. Moreover, CXCR4+ 
was an independent factor predicting poorer progression-free survival in germinal-
center B-cell-like (GCB)-DLBCL, but not in ABC-DLBCL; and in patients with an IPI 
of ≤2, but not in those with an IPI>2. The lack of prognostic significance of CXCR4 
in ABC-DLBCL was likely due to the activation of p53 tumor suppressor attenuating 
CXCR4 signaling. Furthermore, concurrent CXCR4+ and BCL2 translocation showed 
dismal outcomes resembling but independent of MYC/BCL2 double-hit DLBCL. Gene 
expression profiling suggested that alterations in the tumor microenvironment and 
immune responses, increased tumor proliferation and survival, and the dissemination 
of CXCR4+ tumor cells to distant organs or tissues were underlying molecular 
mechanisms responsible for the CXCR4+ associated poor prognosis.
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mediated chemoresistance, but also has direct cytotoxic 
activities in non-Hodgkin lymphoma cell lines, leukemic 
and multiple myeloma cells in a CXCR4-dependent and 
dose-dependent manner [29,37]. 
RESULTS
CXCR4 and CXCL12 expression
IHC results (representative positive and negative 
staining was shown in Figures 1A-C) indicated that 
in most of the DLBCLs, CXCR4 surface expression 
level was low (Figure 1D, Supplemental Figures 1A-
B). The mean expression level in the 468 DLBCLs 
of the training set was 20% of tumor cells positive for 
CXCR4 cell surface expression, which was used as the 
cutoff for CXCR4 overexpression (CXCR4+). Using this 
cutoff (≥20%), we found that 28.8% of the samples in the 
training cohort were CXCR4+.
CXCR4 cell surface expression and mRNA levels 
were higher in the ABC than GCB subtype, whereas 
CXCL12 mRNA levels did not differ significantly between 
the two groups (Figures 1E-F, Supplemental Figure 1C). 
CXCR4 expression detected via IHC was significantly 
correlated with CXCR4 mRNA levels (P < .0001, 
Supplemental Figure 1D), and intriguingly, significantly 
correlated with lower CXCL12 mRNA levels (Figure 1G).
Figure 1: Expression and prognostic significance of CXCR4 in DLBCL. (A-C) Representative CXCR4 immunohistochemistry 
staining (showing 100%, 60%, 0% CXCR4 cell surface expression in DLBCL cells). (D) Histogram of CXCR4 expression frequency 
distribution in the DLBCL study cohort. X-axis, percentage of immunopositive cells in tumors; Y-axis, numbers of DLBCL patients. 
(E-F) ABC-DLBCL compared to GCB-DLBCL had increased CXCR4 cell surface expression, but did not differ in CXCL12 mRNA 
significantly. (G) CXCR4 cell surface expression correlated with decreased CXCL12 mRNA levels, both in GCB- and ABC-DLBCL. (H-
I) CXCR4 expression correlated with significantly poorer OS and PFS in the overall DLBCL cohort. (J-K) CXCR4 expression correlated 
with significantly poorer PFS (but not OS) in GCB-DLBCL. (L-M) CXCR4 expression correlated with significantly poorer OS (but not 
PFS) in ABC-DLBCL. (N-O) CXCR4 expression correlated with significantly poorer survival in DLBCL patients with a low IPI, but not 
in DLBCL patients with a high IPI.
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Clinicopathologic features of patients with 
CXCR4 expression
Clinically, CXCR4+ group had higher proportion 
of male patients and patients with bulky tumors than 
the CXCR4–group, and tended to have higher frequency 
of >1 extranodal involvement (P= .089) (Table 1). 
Pathologically, CXCR4+ GCB-DLBCLs compared to 
CXCR4– GCB-DLBCLs more frequently had a high 
Ki-67 index, TP53 mutations, Myc overexpression and 
less frequently expressed BLIMP-1 or nuclear RelB. 
In comparison, CXCR4+ ABC-DLBCLs compared to 
CXCR4– ABC-DLBCLs had a higher percentage of 
patients with a high Ki-67 index, p53, Myc, Bcl-2, PI3K 
expression and lower occurrence of BCL6 translocations 
and nuclear p50 expression (Table 2). 
CXCR4 expression was associated with 
significantly poorer survival
CXCR4+ DLBCL patients had significantly poorer 
overall survival (OS) (P= .0016) and progression-free 
survival (PFS) (P= .0017) in the study group (Figures 
1H-I). When examined in the GCB and ABC subtypes, 
the adverse impact was significant for the PFS of patients 
with CXCR4+ GCB-DLBCL (Figure 1K), and the OS 
of patients with CXCR4+ ABC-DLBCL (Figure 1L). 
Further multivariate analysis adjusting for clinical factors 
of the study cohort indicated that CXCR4+ remained as 
an independent prognostic factor for significantly poorer 
OS (P= .02) and PFS (P= .03) in the overall DLBCL; 
However, only in GCB- but not in ABC-DLBCL patients, 
CXCR4+ expression was as an independent prognostic 
factor for poorer PFS (P= .025). Interestingly, only in 
patients with ABC-DLBCL was CXCR4+ expression 
associated with wide-type (WT) p53 expression in the 
study cohort (Supplemental Figure 1E, Table 2).
International Prognostic Index (IPI) score appeared 
to be a determinant of CXCR4 prognostic significance. 
Only in patients with an IPI ≤2 was CXCR4+ expression 
associated with significantly poorer OS (Figure 1N) and 
PFS (P= .0002). In patients with an IPI >2, CXCR4+ 
expression did not have distinguishable prognostic 
significance (OS, P= .88, Figure 1O; PFS, P= .91).
Since CXCL12 gradients differ in lymph nodes, 
BM, and other tissues affecting chemotaxis, we analyzed 
the prognostic impact of CXCR4 expression in lymph 
nodes and extranodal sites separately (Figures 2A-B 
showed CXCR4 cell surface expression and CXCL12 
mRNA levels in nodal vs primary extranodal patients). 
Although CXCR4 cell surface expression invariably 
correlated with lower CXCL12 mRNA levels in both 
nodal and extranodal sites (Figure 2C), CXCR4+ 
expression correlated with significantly poorer OS and 
PFS only in nodal DLBCLs (Figures 2E-H) regardless of 
extranodal involvement status (Supplemental Figure 1F). 
In contrast, CXCR4 surface expression was negatively 
correlated with CXCL12 mRNA levels only in patients 
without BM involvement (Figure 2D). However, the 
prognostic significance of CXCR4 in nodal DLBCL 
was demonstrated in both groups either with or without 
BM involvement at diagnosis (Figures 2I-L). Together, 
these data suggested that the prognostic significance of 
CXCR4 expression is independent of BM or extranodal 
involvement, and reduction of CXCL12 mRNA levels in 
the primary sites.
Association and synergy among CXCR4, Bcl-2, 
and Myc expression in GCB-DLBCL
CXCR4, Myc and Bcl-2 expression showed 
association in both the GCB and ABC subtypes (Figures 
3A-H). Myc and Bcl-2 expression, and MYC and BCL2 
translocation have been correlated with poor clinical 
outcomes [38-40]. We therefore assessed the dependency 
and synergism among the prognostic impact of CXCR4, 
Myc, and Bcl-2 expression. 
Although the inverse correlation between CXCR4 
surface expression and CXCL12 mRNA levels was 
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independent of Bcl-2/Myc expression status (Supplemental 
Figures 3A-D), CXCR4+ expression correlated with 
significantly poorer survival in patients with Bcl-2+ GCB-
DLBCL (Figures 3I-J) or Bcl-2– ABC-DLBCL, but not in 
patients with Bcl-2– GCB-DLBCL or Bcl-2+ ABC-DLBCL 
(Supplemental Figure 2). Within the GCB-DLBCL group, 
in which CXCR4+ and BCL2 translocations are prognostic 
[40], CXCR4 expression showed remarkable synergism 
with BCL2 translocations (Figures 3K-L), in a manner 
no less significant than the synergism between MYC and 
BCL2 translocations (Figure 3M). 
Similarly, CXCR4 expression was synergistic with 
Myc overexpression (Figure 3N); however, when the 
group was classified into GCB and ABC subtypes, this 
result did not remain statistically significant (Supplemental 
Figures 1G-J). 
Among Myc+/Bcl-2+ patients, CXCR4 expression 
had an additive adverse impact in patients with GCB-
DLBCL (Figures 3O-P, P= .08 for OS and P= .06 for 
PFS), but this impact was not statistically significant in 
patients with ABC-DLBCL (Supplemental Figures 1K-L).
Association of CXCR4 expression with TP53 
mutations in GCB-DLBCL
In CXCR4+ GCB-DLBCL, the frequency of TP53 
mutations (which correlated with poor clinical outcomes 
[41]) was much higher than in CXCR4– GCB-DLBCL 
(38.3% vs 21.3%, P= .017, Table 2). However, the adverse 
impact of CXCR4 expression was independent of TP53 
mutations (Supplemental Figure 3G-H). Conversely, 
patients with mutated (MUT)-p53 expressed higher 
CXCR4 levels and lower CXCL12 mRNA levels than 
patients with WT-p53, with significant P values within the 
GCB subtype (Figures 4A-C). 
Blimp-1 was another tumor suppressor that 
was significantly downregulated in CXCR4+ GCB-
DLBCL (Figures 4D-E), and this downregulation may 
also contribute to the prognostic impact of CXCR4 
overexpression.
Multivariate survival analysis of CXCR4, Myc, 
Bcl-2, and TP53 mutations 
Since CXCR4 expression was associated with Myc/
Bcl-2 expression and TP53 mutations, all of which are 
adverse prognostic factors, multivariate survival analysis 
Figure 2: Expression and prognostic significance of CXCR4 in nodal and extranodal DLBCL. (A-B) CXCR4 cell surface 
and CXCL12 mRNA expression levels in nodal and extranodal DLBCL. (C) CXCR4 cell surface expression correlated with decreased 
CXCL12 mRNA levels, both in nodal and extranodal DLBCL. (D) CXCR4 cell surface expression correlated with decreased CXCL12 
mRNA levels in DLBCL patients without bone marrow (BM) involvement. (E-F) CXCR4 expression correlated with significantly poorer 
OS and PFS in the nodal DLBCL. (G-H) CXCR4 expression in extranodal sites did not correlate with survival significantly in DLBCL. 
(I-L) the prognostic significance of CXCR4 expression was independent of BM involvement.
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of the pathological factors (including CXCR4+, Myc+, 
Bcl-2+ and TP53 mutations) and the clinical parameters 
(including IPI, gender, tumor size, and B symptoms) was 
performed, which indicated CXCR4 was an independent 
prognostic factor for disease progression (hazard ratio 
1.56, 95% confidence interval of rate 1.13-2.46, P= .008. 
Table 3). 
However, when dissected in the GCB and ABC 
subtypes, the independent prognostic significance of 
CXCR4+ was limited to GCB-DLBCL (P= .04 for PFS); 
in ABC-DLBCL, Myc and Bcl-2 overexpression and TP53 
mutations but not CXCR4 expression, independently 
predicted poorer survival (Table 3). 
We validated the prognostic significance of CXCR4 
in an independent DLBCL cohort (n=275) and confirmed 
that the prognostic significance of CXCR4 was most 
common in patients with an IPI ≤2, depended on Bcl-2 
overexpression in GCB-DLBCL, and had synergy with 
Myc expression (Supplemental Figure 4).
Differentially expressed genes in CXCR4+ versus 
CXCR4– DLBCL patients 
We compared the GEP of CXCR4+ and CXCR4– 
DLBCLs, and found that 447 genes were significantly 
differentially expressed with a false discovery rate 
(FDR) threshold .01 and a fold change cutoff of over 
1.41 (Table 4). Likely owing to the significantly reduced 
CXCL12 expression, which facilitates T cell infiltration 
and trafficking, the GEP of patients with CXCR4+ 
DLBCL revealed remarkably lower expression of T-cell 
and innate immune response biomarkers (MHC class II 
molecules HLA-DQA1/HLA-DQA2, HLA-DRB1/HLA-
DRB4, TRBC1, GIMAP1, FYN, FYB, LCP2, CD3E, 
SIRPG, C3, LAT, MAF, and SAMHD1 involved in antigen 
presentation and T cell signaling) indicating worse 
Figure 3: Association of CXCR4 expression with Myc/Bcl-2 expression and the synergism of prognostic significance 
in DLBCL. (A-D) Association between CXCR4 and Myc expression levels. (E-H) Association between CXCR4 and Bcl-2 expression 
levels. (I-J) CXCR4 expression synergized with Bcl-2 expression in GCB-DLBCL. (K-L) CXCR4 expression synergized with BCL2 
translocation in GCB-DLBCL. (M) The synergism between BCL2 translocation and CXCR4 expression was independent of double-hit 
MYC/BCL2 translocations. (N) CXCR4 expression synergized with Myc expression in DLBCL. (O-P) the prognostic significance of 
CXCR4 in GCB-DLBCL patients with concurrent Myc/Bcl-2 expression.
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prognosis [42], and cell adhesion genes. In addition, 
CXCR4 gene signatures also included upregulated 
survival genes and downregulated pro-apoptosis genes 
in CXCR4+ tumor cells. Upregulated genes included SFN 
(2.57 fold) which stimulates the Akt/mTOR pathway, 
HELLS which is involved in lymphoid cell survival (1.55 
fold), Myc-responsive gene CDCA7 which contributes to 
the Myc-mediated tumorigenesis (1.51 fold), oncogenic 
transcription factor AFF3 (1.45 fold), FAM72A which 
regulates cell growth (1.44 fold), and antipoptotic PEG10 
(1.85 fold). In contrast, pro-apoptotic RASSF4 was 
downregulated (1.42 fold). AICDA, encoding activation-
induced cytidine deaminase which mediates somatic 
hypermutation and class-switch recombination, was 
upregulated by 2.92 fold in patients with CXCR4+ DLBCL 
(3.32 fold in ABC-DLBCL and 2.12 fold in GCB-DLBCL, 
Figures 4F-G). Furthermore, these signatures largely 
overlapped the differentially expressed genes (DEGs) 
identified between CXCR4+ and CXCR4– DLBCL patients 
with an IPI ≤2 (Supplemental Figure 3I and Table 5), 
whereas no DEGs were identified between CXCR4+ and 
CXCR4– DLBCLs with an IPI >2.
GCB-DLBCL and ABC-DLBCL have distinct 
molecular programs, therefore, CXCR4 expression 
signatures were further identified in the GCB and ABC 
subsets separately (Figures 4H-I and Table 4). The 
immunosuppressive, proliferative, and antiapoptotic 
CXCR4 signatures were observed in both GCB and ABC 
subtypes. In GCB-DLBCL, downregulation of FYB, LCP2, 
LILRB2, SAMHD1, and HLA-E, suggested decreased 
adaptive and innate immune responses. In ABC-DLBCL, 
downregulation of FYN, FYB, TRBC1, STAT4, C2, and 
LST1, suggested decreased adaptive immune responses. In 
ABC-DLBCL, the proliferation and antiapoptotic CXCR4 
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signatures were remarkable, such as upregulation of genes 
involved in the cell cycle progression, mitosis, translation, 
metabolism and antiapoptosis (including CDK2, HELLS, 
CCDC52, FARSA, hypoxia-inducible lipid-droplet-
associated protein [HILPDA], PEG10, PIM2, and 
BECN1), and downregulation of the mTORC1 inhibitor 
TXNIP, the tumor suppressors BCL11B and TBRG1. 
The involvement of the Myc and TP53 pathways in the 
CXCR4 signaling was suggested by the upregulation of 
PIM2, which increases Myc stability and transcriptional 
activity, and the downregulation of BCL11B and TBRG1, 
which activate p53. 
Many genes were differentially regulated in GCB 
and ABC subtypes, including the ones involved in the 
PI3K pathway (Figures 4J-L), MAPK signaling, NF-κB 
and angiogenesis (Table 4). In GCB-DLBCL, positive 
regulation of the MAPK pathway by CXCR4 expression 
was suggested by the upregulation of DOK5, PTHLH 
(which transports calcium), and STIM2 (which activates 
Ca2+ entry channels) and the downregulation of its 
negative regulator DUSP4. In contrast, in ABC-DLBCL, 
negative regulation of MAPK by CXCR4 signaling was 
indicated by the downregulation of FYN upstream of 
the MAPK signaling pathway, and the downregulation 
of calcium-dependent molecules such as MFAP4. In the 
GCB subtype, CYLD and UBD which activate NF-κB 
Figure 4: Regulation of and signaling pathways related to CXCR4 expression. (A-C) p53 mutations were associated increased 
CXCR4 and decreased CXCL12 mRNA expression, especially in GCB-DLBCL. (D-E) CXCR4 expression was associated with decreased 
PRDM1 mRNA and BLIMP-1 expression in GCB-DLBCL. (F) CXCR4 expression was associated with increased AICDA mRNA expression 
both in GCB- and ABC-DLBCL. (G-H) Heatmaps and differentially expressed genes between CXCR4+ and CXCR4- patients in the overall 
DLBCL, GCB-DLBCL and ABC-DLBCL cohorts. (J-K) CXCR4 expression was associated with increased PI3K mRNA expression in 
GCB-DLBCL, and increased protein expression in ABC-DLBCL.
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were downregulated in CXCR4+ compared to CXCR4– 
DLBCL patients. In the ABC subtype, NF-κB pathway 
showed opposite regulations: NF-κB activators CARD11 
and PIM2 were upregulated, whereas TNFSF12, TNFSF8 
and IL12RB were downregulated (Figure 4I, Supplemental 
Figures 3J-L). In CXCR4+ GCB-DLBCL, PTPN6/PTN6 
which modulates epidermal growth factor receptor was 
downregulated whereas in CXCR4+ ABC-DLBCL, 
HILPDA which activates vascular endothelial growth 
factor A was upregulated. 
Pathway analysis (http://www.qiagen.com/
ingenuity) indicated CXCR4 signatures were associated 
with functional networks of cell-to-cell signaling and 
interaction, immune cell trafficking, hematological 
system development and function, cellular growth and 
proliferation, cell death and survival (Supplemental Figure 
5).
Effect of CXCR4 inhibitor BKT140 on the growth 
of DLBCL cells
We assessed the effect of the CXCR4 inhibitor 
BTK140 on growth of DLBCL cells. In 10 cell lines of 
either the GCB or ABC subtype, BKT140 treatment 
resulted in a significant dose-dependent growth inhibition 
in all 10 cell lines, with half maximal inhibitory 
concentration values ranging from 16.55 to 79.33 nM; 
however, the inhibition did not appear to depend on 
CXCR4 expression (Figure 5A-B). BTK140 indeed 
inhibit CXCR4-mediated cell adhesion, suggested by the 
alteration of growth patterns of DLBCL cells expressing 
high CXCR4 mRNA. The proliferation pattern of DLBCL 
cells changed from adhesive to discohesive after 48 hours 
of incubation with different concentrations of BKT140 
(Figure 5C). 
Figure 5: Effects of BTK140 on proliferation and the growth patterns of DLBCL cells. (A) Expression levels of CXCR4 
mRNA in DLBCL cell lines. (B) Ten DLBCL cell lines were treated with BTK140 in a dose-dependent manner. Cell proliferation was 
measured using 3H-thymiding incorporation assay after 72 hours incubation. Dates shown are the means and ranges of triplicate samples 
relative to control samples of three independent experiments. (C) The proliferation pattern of McA cells incubated without BKT140 (i), 
with 6.25uM BKT140 (ii), and with 50uM BKT140 (iii). (C) The proliferation pattern of LY19 incubated without BKT140 (I), with 6.25uM 
BKT140 (II), and with 50uM BKT140 (III).
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DISCUSSION 
The CXCR4/CXCL12 axis is essential for 
development, hematopoiesis, vascularization [4], and 
migration, homing and retention of stem cells. In the 
current study, CXCR4 expression was associated with 
poorer OS (P= .0016) and PFS (P= .0017) in a large cohort 
of 468 de novo DLBCL patients treated with R-CHOP 
(Figures 1H-I) and poorer therapy response in 236 
GCB-DLBCLs. However, although univariate analysis 
of CXCR4 expression showed prognostic significance 
in both GCB and ABC subtypes, multivariate analysis 
indicated that CXCR4 expression was an independent 
prognostic factor for poorer PFS only in GCB-
DLBCL patients. Furthermore, our data suggested that 
concurrent CXCR4 expression and BCL2 translocation 
may represent another type of double-hit DLBCL with 
aggressive clinical courses. In ABC-DLBCL, Myc/
Bcl-2 expression and TP53 mutations but not CXCR4 
expression independently predicted poor survival. The 
lack of independent prognostic significance of CXCR4 
expression in ABC-DLBCL was likely due to the tumor 
suppression function of WT-p53 whose expression was 
associated with CXCR4+ in ABC-DLBCL. It may also be 
attributed to the significantly (P= .0047) higher proportion 
of patients with an IPI>2 in ABC (68.4%) than in GCB 
(55%), as the prognostic significance and biologic impact 
of CXCR4 expression was only demonstrated in patients 
with low-risk IPI.
It is widely accepted that the CXCR4/CXCL12 
axis underlies the decreased chemosensitivity and disease 
progression, by directing CXCR4-expressing tumor cells 
through concentration gradients of CXCL12 to reside 
in protective niche (such as BM and lymph nodes). Our 
results showed that CXCR4 expression had a significant 
prognostic impact in nodal DLBCL but not extranodal 
DLBCL. However, only 10.7% CXCR4+ patients showed 
BM involvement at diagnosis, and the adverse impact of 
CXCR4 expression in nodal DLBCL is independent of BM 
involvement, suggesting other malignant consequences 
besides BM homing ensuing CXCR4 expression in 
DLCBL. In patients without BM involvement, we 
surprisingly observed an inverse correlation between 
CXCR4 surface expression and CXCL12 mRNA 
expression in stromal cells. This paradoxical phenomenon 
was also observed in primary kidney tumor tissues [43]. 
We speculate that the abnormal CXCR4high/CXCL12low 
condition at the primary sites lead to the dissemination 
of CXCR4+ lymphoma cells to distant organs expressing 
higher CXCL12, which resulted in disease progression 
of CXCR4+ DLBCL. Supporting this hypothesis, 
CXCL12 expression was a strong independent prognostic 
biomarker for better survival in breast cancers [44], and 
administration of CXCL12 has been suggested as a potent 
inhibitor of colorectal and melanoma metastasis [45]. 
In addition, CXCR4+ demonstrated different prognostic 
values in different disease subsets although it consistently 
correlated with decreased CXCL12 mRNA levels in these 
subsets (Figures 2, 3, Supplemental Figures 2, 3A-D). 
Therefore, CXCL12 reduction alone may be insufficient 
to account for the CXCR4-associated disease progression. 
Furthermore, our protein expression and GEP data 
suggested that the impact of CXCR4 on lymphoma relapse 
and progression of de novo DLBCL may be attributed to 
dysregulations in both the tumor microenvironment and 
the tumor cells themselves. These mechanisms used by 
CXCR4 for tumor cell survival may include reduced 
immune surveillance, increased tumor proliferation 
involving the upregulation of the Myc and PI3K/
mTOR pathways, and blocked apoptosis involving Bcl-
2 expression and the TP53 pathway. Previous studies 
showed that p53 negatively regulated expression of 
CXCR4 [2] (consistent with our results) and CXCL12 
[46,47] (inconsistent with our mRNA results) abrogating 
the stromal cell-mediated chemoresistance. The role 
of CXCR4 signaling in promoting proliferation and 
survival was supported by the in vitro studies, where the 
high-affinity CXCR4 inhibitor BTK140 alone resulted 
in inhibited proliferation as well as inhibitory changes 
of adhesion and growth patterns in various DLBCL cell 
lines. These novel oncogenic mechanisms, in addition 
to the dissemination of CXCR4+ tumor cells to distant 
lymphatic tissues with high CXCL12 concentrations, may 
synergistically account for the CXCR4-mediated disease 
progression.
In cancer cells, CXCR4 expression can be caused by 
hypoxia, NF-κB activation, and ubiquitination inhibition 
[4]. In some patients of our cohort, increased CXCR4 
expression may have resulted from reduced degradation, 
as suggested by decreased expression of UBD/ubiquitin D 
and the deubiquitinating enzyme CYLD in GCB-DLBCL 
and decreased E3 ubiquitin-protein ligase MARCH2 in 
ABC-DLBCL. In ABC-DLBCL, upregulated SUGT1, 
which plays a role in ubiquitination and subsequent 
proteasomal degradation of target proteins, may counteract 
the CXCR4 increase. Hypoxia (as suggested by increased 
HILPDA) which is known for CXCR4 activation [3,4,9], 
may also be the causes of CXCR4 expression in ABC-
DLBCL.
Cell-of-origin may as well explain the CXCR4+ 
phenotype. Some CXCR4+ GCB-DLBCLs may represent 
lymphoma cells arising from CXCR4high centroblasts in the 
CXCL12-rich dark zone and CXCR4– GCB-DLBCLs may 
be the transformed CXCR4low centrocytes in the light zone, 
where B cells interact with follicular dendritic and T helper 
cells. This hypothesis is in line with the higher activation-
induced cytidine deaminase levels, highly proliferative 
characteristics, and the lack of T cell signature in CXCR4+ 
patients [23,24], but is contradicted by the CXCR4+ 
associated low CXCL12 levels. A plausible explanation 
is that abnormal reduction in CXCL12 expression in 
lymph nodes (due to oncogenic mechanisms such as 
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dysregulated TNF cytokines or Myc overexpression, 
or as the secondary event of BCL2 translocation in the 
GC) initiated the tumorigenesis. This was selected for 
CXCR4high lymphoma cells due to the dynamics of 
CXCL12/CXCR4 equilibrium and led to decreased T cell 
infiltration and deficient immune responses due to reduced 
chemoattraction, cooperating with the CXCR4-associated 
pro-survival signals. Decreased CXCL12 expression 
further led to dissemination of CXCR4+ tumor cells to 
distant lymphatic tissues with higher CXCL12 expression 
[28, 51]. Therefore, the abnormal CXCL12/CXCR4 levels 
may be relevant for both lymphomagenesis and disease 
progression. 
In conclusion, our results indicated CXCR4 
expression was associated with poorer clinical outcomes in 
DLBCL and independently predicted disease progression 
in GCB-DLBCL. The underlying mechanisms whereby 
CXCR4 exerts its prognostic impact may include tumor 
growth promotion, apoptosis inhibition, decreased T 
cell infiltration and immune responses, and tumor cell 
dissemination to distant organs/tissues. These results could 
help stratify DLBCL and gain insight of molecular events 
that function as therapeutic targets.
PATIENTS AND METHODS
Patients 
The training study consisted of 468 patients with 
de novo DLBCL diagnosed between 2000 and 2010 
and treated with R-CHOP (median age: 63 years). 
The diagnostic criteria, review process, eligibility and 
exclusion criteria, cell-of-origin classification as either 
GCB or ABC subtype via GEP or IHC algorithms have 
been described previously [38,41,48]. At last follow-
up, 176 of 468 (37.6%) patients had died. The median 
follow-up for the 292 censored patients was 48.7 months. 
For validation, an independent cohort of 275 de novo 
DLBCLs diagnosed between 2002 and 2007 and treated 
with R-CHOP was used, with median follow-up of 50 
months. This study was conducted in accordance with 
the Declaration of Helsinki and was approved as being 
of minimal to no risk or as exempt by the Institutional 
Review Boards of all participating centers, including The 
University of Texas MD Anderson Cancer Center. 
CXCR4 cell surface expression and other 
pathological experiments
IHC analyses for CXCR4 expression using 
polyclonal anti-CXCR4 antibody (Abcam) and antihuman 
CXCR4 mAb (R&D Systems) were performed on tissue 
microarrays of formalin-fixed, paraffin-embedded 
(FFPE) lymphoma samples and was assessed by three 
pathologists blinded from clinical outcomes with similar 
results. The inter-observer agreement was 98%, and the 
disagreement was resolved by joint review at a multi-
headed microscope. 
IHC of other biomarkers using respective 
monoclonal antibodies, fluorescence in situ hybridization 
to detect MYC, BCL6, and BCL2 translocations, and TP53 
resequencing using p53 AmpliChip have been described 
previously [38-41,48,49].
Gene expression profiling 
GEP by the Affymetrix GeneChip Human Genome 
U133 Plus 2.0 array was performed using total RNAs 
extracted from FFPE tissues as previously described [38-
41,48,49]. Normalized microarray data were analyzed 
for differential gene expression between the CXCR4+ 
and CXCR4– groups. Univariate analysis using a t test 
was performed to identify differentially expressed genes. 
The P values obtained via multiple t-tests were corrected 
for FDRs using the beta-uniform mixture method. 
Differentially expressed genes were identified at various 
FDRs with different P value cutoffs. Pathway analysis 
for the identified DEGs was performed using Ingenuity® 
Pathway Analysis (IPA®, http://www.qiagen.com/
ingenuity) software program.
Effect of CXCR4 inhibitor BTK140 in vitro
The inhibitory effect of BTK140 (kind gift from 
BioLineRx Ltd, Jerusalem, Israel) was evaluated in 10 
DLBCL cell lines that were either the GCB (DBr, DOHH2, 
SUDHL4, CJ, McA, LY19) or ABC (LY3, WP, LR, and 
LY10) subtype that were cultured and maintained in 
RPMI 1640 (Life Technologies, Rockville, MD, USA) and 
15% fetal calf serum (HyClone, Logan, UT, USA). [3H] 
thymidine proliferation assays in vitro were performed 
as described previously [50]. Different concentrations of 
BKT140 were used: 3.125 µM, 6.25 µM, 12.5 µM, 25 
µM, 50 µM, 100 µM, and 200 µM. Cell proliferation was 
measured using 3H-thymidine incorporation assays after 
72 hours of incubation.
Statistical analysis
The clinicopathologic features of CXCR4+ and 
CXCR4– DLBCL patients at the time of presentation 
were compared using the chi-square test. Overall survival 
was calculated from the time of diagnosis to death from 
any cause or last follow-up. Progression-free survival 
was calculated from the time of diagnosis to disease 
progression, relapse, or death from any cause.21 Patients 
who were alive and/or had no disease progression 
were censored at last follow-up. Survival analysis was 
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performed using the Kaplan–Meier method with GraphPad 
Prism 6 (GraphPad Software, San Diego, CA), and 
differences were compared using the log-rank (Mantel-
Cox) test. Multivariate survival analysis was performed 
using the Cox proportional hazards regression model with 
the SPSS statistics software program (version 19.0; IBM 
Corporation, Armonk, NY). All differences with P ≤ .05 
were considered statistically significant.
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